Cosentyx secukinumab regulatory update

Novartis said Japan approved Cosentyx secukinumab to treat psoriasis vulgaris and psoriatic arthritis in adults who are not responsive to systemic therapies. The pharma said this is the first approval of the human IgG1 mAb targeting IL-17A and the first IL-17A inhibitor approved for either indication in Japan. Novartis declined to disclose details concerning the drug’s price and launch date. ...